Baxter (NYSE:BAX) officials apparently think their company can benefit from a Trump administration and CMS proposal to provide extra reimbursement for new and innovative dialysis equipment and supplies.
Just days ago, CEO Joe Almeida told analysts in an earnings call that the company planned to invest $500 million to significantly increase production capacity and meet new patients’ needs amid the push to adopt home dialysis across the United States.
The proposed CMS rule and the Advancing American Kidney Health Initiative are “putting once-in-a-generation policies in place to improve the lives of those with kidney disease,” Laura Angelini, general manager of Baxter’s Renal Care business, said today in a news release.
